MNPR-101-Zr

N/A

Report date: 2025/09/19 17:44:54

Base Information

Drug NameMNPR-101-Zr
Drug Alias Name89Zr-MNPR-101MNPR-101-ZrMNPR-101-DFO*-89Zr
ClassificationRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Zirconium > 89Zr +[4] 
Mechanisms of ActionPositron-emission tomography enhancers
TargetsUrokinase plasminogen activator surface receptor
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMonopar Therapeutics IncNorthstar Medical Radioisotopes Llc
China Registration ClassN/A

Develop Information

Active CompaniesMonopar Therapeutics IncNorthstar Medical Radioisotopes Llc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A